Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas-Reference-Cited by-同舟云学术

Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas

Published:2014-09-12 Issue:3 Volume:28 Page:446-456
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Tan Hsueh-Li,Haffner Michael C,Esopi David M,Vaghasia Ajay M,Giannico Giovanna A,Ross Hillary M,Ghosh Susmita,Hicks Jessica L,Zheng Qizhi,Sangoi Ankur R,Yegnasubramanian Srinivasan,Osunkoya Adeboye O,De Marzo Angelo M,Epstein Jonathan I,Lotan Tamara L

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2014115.pdf

Reference38 articles.

1. Osunkoya AO, Hansel DE, Sun X et al. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: Report of 21 cases. Am J Surg Pathol 2008;32:461–467.

2. Giannico GA, Ross HM, Lotan T et al. Aberrant expression of p63 in adenocarcinoma of the prostate: A radical prostatectomy study. Am J Surg Pathol 2013;37:1401–1406.

3. Ali TZ, Epstein JI . Basal cell carcinoma of the prostate: A clinicopathologic study of 29 cases. Am J Surg Pathol 2007;31:697–705.

4. Toubaji A, Albadine R, Meeker AK et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 2011;24:1511–1520.

5. Lotan TL, Gurel B, Sutcliffe S et al. PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011;17:6563–6573.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the diagnostic impact of P63, PSA and BCL-2 proteins in premalignant and malignant prostate tissues;International Journal of Scientific Reports;2024-05-23

2. Intraductal Carcinoma of the Prostate versus Simulants: A Differential Diagnosis Growing in Clinical Impact;Cancers;2024-03-08

3. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases;Pathology - Research and Practice;2024-02

4. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall;Histopathology;2023-11-15

5. Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives;Biomedicines;2023-05-26